Your browser doesn't support javascript.
Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia.
Milic, Jovana; Novella, Alessio; Meschiari, Marianna; Menozzi, Marianna; Santoro, Antonella; Bedini, Andrea; Cuomo, Gianluca; Franceschini, Erica; Digaetano, Margherita; Carli, Federica; Ciusa, Giacomo; Volpi, Sara; Bacca, Erica; Franceschi, Giacomo; Yaacoub, Dina; Rogati, Carlotta; Tutone, Marco; Burastero, Giulia; Faltoni, Matteo; Iadisernia, Vittorio; Dolci, Giovanni; Cossarizza, Andrea; Mussini, Cristina; Pasina, Luca; Guaraldi, Giovanni.
  • Milic J; Department of Surgical, Medical, Dental, and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Novella A; Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.
  • Meschiari M; Pharmacotherapy and Appropriateness of Drug Prescription Unit, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Menozzi M; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Santoro A; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Bedini A; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Cuomo G; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Franceschini E; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Digaetano M; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Carli F; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Ciusa G; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Volpi S; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Bacca E; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Franceschi G; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Yaacoub D; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Rogati C; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Tutone M; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Burastero G; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Faltoni M; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Iadisernia V; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Dolci G; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Cossarizza A; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
  • Mussini C; Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.
  • Pasina L; Department of Surgical, Medical, Dental, and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Guaraldi G; Infectious Diseases Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
AIDS Res Hum Retroviruses ; 37(4): 283-291, 2021 04.
Article in English | MEDLINE | ID: covidwho-1207222
ABSTRACT
The aim of this study was to evaluate both positive outcomes, including reduction of respiratory support aid and duration of hospital stay, and negative ones, including mortality and a composite of invasive mechanical ventilation or death, in patients with coronavirus disease 2019 (COVID-19) pneumonia treated with or without oral darunavir/cobicistat (DRV/c, 800/150 mg/day) used in different treatment durations. The secondary objective was to evaluate the percentage of patients treated with DRV/c who were exposed to potentially severe drug-drug interactions (DDIs) and died during hospitalization. This observational retrospective study was conducted in consecutive patients with COVID-19 pneumonia admitted to a tertiary care hospital in Modena, Italy. Kaplan-Meier survival curves and Cox proportional hazards regression were used to compare patients receiving standard of care with or without DRV/c. Adjustment for key confounders was applied. Two hundred seventy-three patients (115 on DRV/c) were included, 75.8% males, mean age was 64.6 (±13.2) years. Clinical improvement was similar between the groups, depicted by respiratory aid switch (p > .05). The same was observed for duration of hospital stay [13.2 (±8.9) for DRV/c vs. 13.4 (±7.2) days for no-DRV/c, p = .9]. Patients on DRV/c had higher rates of mortality (25.2% vs. 10.1%, p < .0001. The rate of composite outcome of mechanical ventilation and death was higher in the DRV/c group (37.4% vs. 25.3%, p = .03). Multiple serious DDI associated with DRV/c were observed in the 19 patients who died. DRV/c should not be recommended as a treatment option for COVID-19 pneumonia outside clinical trials.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Anti-HIV Agents / Darunavir / Cobicistat / COVID-19 Drug Treatment Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: AIDS Res Hum Retroviruses Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 2021 Document Type: Article Affiliation country: Aid.2020.0305

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Anti-HIV Agents / Darunavir / Cobicistat / COVID-19 Drug Treatment Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: AIDS Res Hum Retroviruses Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 2021 Document Type: Article Affiliation country: Aid.2020.0305